Related Experiment Video

Updated: Aug 29, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Key current clinical issues in alpha-1 antitrypsin deficiency

James K Stoller1

  • 1Department of Pulmonary and Critical Care Medicine, A90, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland OH 44195, USA. stollej@ccf.org.

Respiratory Care
|December 4, 2003
PubMed

Insights

Alpha-1 antitrypsin deficiency (AATD) is under-recognized. New standards recommend wider testing and consider augmentation therapy for patients with airflow obstruction, improving AATD diagnosis and care.

Area of Science:

  • Pulmonology
  • Genetics
  • Internal Medicine

Background:

  • Alpha-1 antitrypsin deficiency (AATD) is a prevalent genetic disorder often overlooked.
  • Respiratory therapists play a crucial role in managing AATD.
  • Recent international guidelines address AATD diagnosis and management.

Purpose of the Study:

  • To summarize the international evidence-based standards for AATD diagnosis and management.
  • To highlight recommendations for increased AATD screening.
  • To review evidence on the efficacy of intravenous AATD augmentation therapy.

Main Methods:

  • Review of an international evidence-based standards document.
  • Analysis of evidence regarding the clinical efficacy of intravenous AAT. augmentation therapy.
  • Synthesis of recommendations for AATD diagnosis and treatment.

Main Results:

  • The standards document advocates for broader AATD testing to benefit more patients.
  • Evidence suggests clinical efficacy of AAT augmentation therapy, particularly in moderate airflow obstruction.
  • Intravenous augmentation therapy is recommended in specific clinical situations.

Conclusions:

  • Increased AATD screening is recommended to identify affected individuals.
  • Intravenous augmentation therapy is supported by current evidence for specific patient groups.
  • Adherence to these standards can improve outcomes for individuals with AATD.

More Related Videos

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

Related Concept Videos

Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Acute Pancreatitis II: Pathophysiology01:21

Acute Pancreatitis II: Pathophysiology

The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation